# US 2024/0197908 A1 · Modified extracellular vesicles (evs) with improved half-life

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197908 A1
- Document ID: US20240197908A1
- Status: Published application
- Kind: A1
- Application number: 18/287,206
- Filed: 2022-04-26
- Published: 2024-06-20
- Earliest claimed: 2021-04-26
- Applicants: Evox Therapeutics Limited
- Inventors: Christopher DAVIES; Justin HEAN; Xiuming LIANG
- Web page: https://patentgrep.com/patent/US20240197908A1

## CPC

- A61K 9/1275: Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/643: {Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}
- C12N 5/0662: {Stem cells}
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- A61K 48/0041: {the non-active part being polymeric}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

A modified Extracellular Vesicle (EV), preferably an exosome, comprising an albumin protein or fragment (e.g., an albumin domain) present on the surface of the EV membrane, preferably as part of a fusion protein (e.g., a transmembrane protein). The EV exhibits an improved circulating half-life, stability and shelf-life (both formulation and storage). Methods of making said EVs, as well as pharmaceutical compositions and their use.

## Claims

### Claim 1

An Extracellular Vesicle (EV) modified to comprise an albumin protein present on the surface of the EV.

### Claim 2 (depends on 1)

The EV according to claim 1, wherein the albumin protein forms part of a fusion protein with an EV protein.

### Claim 3 (depends on 2)

The EV according to claim 2, wherein the EV protein is selected from an EV transmembrane protein or EV membrane associated protein.

### Claim 4 (depends on 3)

The EV according to claim 3, wherein the transmembrane protein is a single-pass transmembrane protein or a multi-pass transmembrane protein.

### Claim 5 (depends on 3)

The EV according to claim 3, wherein the transmembrane protein is a tetraspanin.

### Claim 6 (depends on 2)

The EV according to claim 2, wherein the EV protein is selected from one or more of CD44, CD47, CD55, LAMP2B, TFNR, TfR1, CD63, CD81, CD82, CD9, LIMP2, ICAMs, ARRDC1, TSPAN2, TSPAN3 and derivatives, domains, variants, mutants, or regions thereof.

### Claim 7 (depends on 2)

The EV according to claim 2, wherein the albumin protein is fused to the EV protein at the N-terminus, C-terminus, at least a portion of a transmembrane domain, or at least a portion of extravesicular loop of the EV protein.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The EV according to claim 1, wherein the EV comprises a plurality of albumin proteins.

### Claim 10 (depends on 9)

The EV according to claim 9, wherein at least two of the albumin proteins of the plurality of albumin proteins are present in the same fusion protein as each other.

### Claim 11 (depends on 9)

The EV according to claim 9, wherein the albumin proteins are fused to the same extracellular loop of the same fusion protein as one another.

### Claim 12 (depends on 9)

The modified EV according to claim 9, wherein the albumins or modified albumins are fused to a different extracellular loop of the same fusion protein from one another.

### Claim 13 (depends on 9)

The EV according to claim 9, wherein at least two of the albumin proteins of the plurality of albumin proteins are present in a different fusion protein from each other.

### Claim 14 (depends on 1)

The EV according to claim 1, wherein the EV comprises a cargo.

### Claim 15 (depends on 14)

The EV according to claim 14, wherein the cargo is a therapeutic cargo selected from one or more of a peptide, a protein, a nucleic acid, a virus, a viral genome, an antigen, a small molecule or a biologic.

### Claim 16 (depends on 14)

The EV according to claim 14, wherein the cargo is present on the inside of the EV, on the outside of the EV and/or in the membrane of the EV.

### Claim 17 (depends on 14)

The EV according to claim 14, wherein the therapeutic cargo forms part of the albumin fusion protein.

### Claim 18 (depends on 1)

The EV according to claim 1, wherein the EV further comprises a targeting moiety.

### Claim 19 (depends on 17)

The EV according to claim 17, wherein the targeting moiety forms part of the albumin fusion protein.

### Claim 20 (depends on 1)

The EV according to claim 1, wherein the EV is an exosome.

### Claim 21 (depends on 1)

A method for producing the EV according to claim 1, wherein the method comprises the steps of:
(i) introducing into an EV-producing cell at least one polynucleotide construct encoding an albumin-EV protein fusion construct; and
(ii) expressing said construct in the EV-producing cell, thereby generating an EV comprising one or more of an albumin protein present on the surface of the EV.

### Claim 22 (depends on 1)

A pharmaceutical composition comprising at least one EV according to claim 1 and one or more pharmaceutically acceptable excipient, diluent, vehicle, solvent or carrier.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

A method of treating a disease or condition in a subject in need thereof comprising, administering to the subject a therapeutically effective amount of the EV according to claim 1.
